Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Lonza and Bio*One Capital to invest in mammalian cell-culture manufacturing facility
January 29th, 2007
Lonza Group, Ltd., (LONN) and Singapore's Bio*One Capital announce the signing of a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell-culture facility in Singapore for the manufacture of commercial biopharmaceuticals. This will be the second large-scale mammalian manufacturing plant in Singapore, and the third one globally that Lonza has built. Depending upon customer request, the capital investment will amount up to US$350 million. Lonza and Bio*One Capital entered into an initial joint venture in February 2006 to build an 80,000 liter large-scale mammalian biopharmaceutical production facility named Lonza Biologics Singapore, Pte, Ltd. This...
Source: Biotech Business Week (2007-01-29)
|
